Collegium Announces $100 Million Share Repurchase Program
August 16, 2021 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...
Collegium Reports Strong Q2 Results with Cash Balance Growing to Over $200 Million
August 05, 2021 16:01 ET
|
Collegium Pharmaceutical, Inc.
– Xtampza® ER Market Share Grew to 31.5% of the Oxycodone Extended-Release Market in June 2021 – – Net Income of $72.8 Million and Adjusted EBITDA of $40.1 Million – – Full-Year 2021 Product Revenue...
Collegium to Host Conference Call to Discuss Second Quarter 2021 Financial Results and Provide Corporate Update
July 21, 2021 16:01 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., July 21, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live webcast on Thursday, August 5,...
Collegium Announces Publication of Real-World Data in Journal of Pain Research
June 16, 2021 16:01 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...
Collegium to Participate in Upcoming Investor Conference
May 20, 2021 16:05 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...
Collegium Reports Record Quarterly Revenue of $87.7 Million
May 06, 2021 16:01 ET
|
Collegium Pharmaceutical, Inc.
– Net Income of $15.7 Million and Adjusted EBITDA of $45.3 Million in the First Quarter of 2021 – – Nucynta® Franchise and Adjusted EBITDA 2021 Guidance Range Raised – – Colleen Tupper Appointed...
Collegium to Host Conference Call to Discuss First Quarter 2021 Financial Results and Provide Corporate Update
April 15, 2021 16:01 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday,...
Collegium Reports Record Full-Year 2020 Revenue of $310.0 Million
February 25, 2021 16:01 ET
|
Collegium Pharmaceutical, Inc.
– 2020 First Full-Year of Profitability, Driven by Xtampza® ER Revenue Growth and the Nucynta® Acquisition – – Collegium Reiterates Previously Issued 2021 Guidance – – Conference Call Scheduled for...
Collegium to Host Conference Call to Discuss Fourth Quarter 2020 Financial Results and Provide Corporate Update
February 11, 2021 16:01 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday,...
Collegium Provides 2021 Financial Guidance
January 06, 2021 16:01 ET
|
Collegium Pharmaceutical, Inc.
– Xtampza® ER Revenues Expected in the Range of $155.0 million to $165.0 million – – Nucynta® Franchise Revenues Expected in the Range of $175.0 million to $185.0 million – – Adjusted EBITDA...